Gary Hattersley Biography and Net Worth

Chief Scientific Officer of Nuvation Bio

Dr. Hattersley joined Nuvation Bio in 2019 following a 15-year career at Radius Health Inc, where he supported the development of its oncology and women’s health portfolio, including TYMLOS®, approved by the FDA in 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. At Radius Health, Dr. Hattersley held roles of increasing seniority, including Chief Scientific Officer, Senior Vice President of Preclinical Development, and Vice President of Biology. Prior to Radius Health, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals, where he had responsibility for the discovery and development of novel small molecule agents for the treatment of metabolic bone diseases. He also held positions at Genetics Institute investigating the application of the bone morphogenetic proteins in musculoskeletal disease. Dr. Hattersley received a Ph.D. from St. George’s Hospital Medical School in London.

How old is Gary Hattersley?: Dr. Hattersley is currently 57 years old. There are 8 older executives and no younger executives at Nuvation Bio. The oldest executive at Nuvation Bio is Dr. David T. Hung M.D., Founder, President, CEO & Director, who is 66 years old. Learn More on Gary Hattersley's age.
How do I contact Gary Hattersley?: The corporate mailing address for Dr. Hattersley and other Nuvation Bio executives is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. Nuvation Bio can also be reached via phone at 332-208-6102 and via email at [email protected]. Learn More on Gary Hattersley's contact information.
Has Gary Hattersley been buying or selling shares of Nuvation Bio?: During the past quarter, Gary Hattersley has sold $502,000.00 in Nuvation Bio stock. Most recently, Gary Hattersley sold 100,000 shares of the business's stock in a transaction on Monday, October 27th. The shares were sold at an average price of $5.02, for a transaction totalling $502,000.00. Learn More on Gary Hattersley's trading history.
Who are Nuvation Bio's active insiders?: Nuvation Bio's insider roster includes Kim Blickenstaff (Director), Xiangmin Cui (Director), Jennifer Fox (CFO & Sec. ), Gary Hattersley (Chief Scientific Officer), David Hung (Founder), David Hung (CEO), Robert Mashal (Director), and Oleg Nodelman (Director). Learn More on Nuvation Bio's active insiders.
Are insiders buying or selling shares of Nuvation Bio?: During the last year, Nuvation Bio insiders bought shares 2 times. They purchased a total of 500,000 shares worth more than $818,000.00. During the last year, insiders at the sold shares 8 times. They sold a total of 340,000 shares worth more than $2,100,800.00. The most recent insider tranaction occured on December, 1st when insider Dongfang Liu sold 150,000 shares worth more than $1,173,000.00. Insiders at Nuvation Bio own 29.9% of the company. Learn More about insider trades at Nuvation Bio.
Information on this page was last updated on 12/1/2025.

Gary Hattersley Insider Trading History at Nuvation Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/27/2025	Sell	100,000	$5.02	$502,000.00

Gary Hattersley Buying and Selling Activity at Nuvation Bio

Nuvation Bio Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Today's Range

Now: $8.37

$8.00

$8.55

50 Day Range

MA: $5.69

$3.41

$8.60

2 Week Range

Now: $8.37

$1.54

$8.95

Volume

6,074,546 shs

Average Volume

9,740,624 shs

Market Capitalization

$2.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57